Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05701488 · ClinicalTrials.gov registry record · Phase 1
SIRT With Tremelimumab and Durvalumab for Resectable HCC
A Phase 1 study of Hepatocellular Carcinoma and Hepatocellular Cancer, sponsored by Jiping Wang, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT05701488: Recruiting Phase 1 study of Hepatocellular Carcinoma and Hepatocellular Cancer, sponsored by Jiping Wang, MD, PhD.
NCT05701488 is a Phase 1 study of Hepatocellular Carcinoma and Hepatocellular Cancer that is actively recruiting participants, run by Jiping Wang, MD, PhD. The registered enrollment target is 20 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05701488, a Phase 1 study of Hepatocellular Carcinoma and Hepatocellular Cancer, is actively recruiting participants, sponsored by Jiping Wang, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventions involved in this study are: * Durvalumab (a type of immunotherapy) * Tremelimumab (a type of immunotherapy) * Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)
Primary Outcome
Defined as All grade 3-5 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3-5 AE of any type during the time of observation.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
- DEVICE SIRT
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 1 |
What NCT05701488 shows while recruiting
NCT05701488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.
NCT05701488 reports a single indexed study location in Massachusetts, California.
Frequently Asked Questions
What is clinical trial NCT05701488 about?
NCT05701488 is a clinical study titled "SIRT With Tremelimumab and Durvalumab for Resectable HCC". The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery. The names of the interventi...
What is the current status of trial NCT05701488?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-04-21. Estimated completion is 2026-10-01.
What conditions does trial NCT05701488 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Resectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05701488?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), SIRT (DEVICE).
Who is sponsoring clinical trial NCT05701488?
This trial is sponsored by Jiping Wang, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05701488 being conducted?
This trial has 3 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05701488's enrollment target sits among peer trials
20 123rd of 145 higher than 16 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI